The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myeloma
2017 · Haematologica · 78 citations
https://doi.org/10.3324/haematol.2017.168872
M
Michael Bauer
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
396
Papers
3.3K
Citations
24
h-index
47
i10-index
Michael Bauer is an academic researcher from University of Arkansas for Medical Sciences. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Protein Degradation and Inhibitors & HIV/AIDS drug development and treatment. The author has an h-index of 24, co-authored 337 publications.
ORCID: 0000-0003-2498-7295Papers by this author
worksBi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
2017 · Blood Cancer Journal · 59 citations
https://doi.org/10.1038/bcj.2017.12
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
2024 · Blood Cancer Journal · 24 citations
https://doi.org/10.1038/s41408-024-01172-x
Towards the integration, annotation and association of historical microarray experiments with RNA-seq
2013 · BMC Bioinformatics · 18 citations
https://doi.org/10.1186/1471-2105-14-s14-s4
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
2023 · Cell Reports Medicine · 17 citations
https://doi.org/10.1016/j.xcrm.2023.101214
NATbox: a network analysis toolbox in R
2009 · BMC Bioinformatics · 16 citations
https://doi.org/10.1186/1471-2105-10-s11-s14
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat